Inquiry Basket
Loading ......
The parathyroid hormone 1 receptor, universally abbreviated PTH1R, is a cell-surface receptor that sits at the center of how the body measures and manages its calcium. It belongs to the large family of G protein-coupled receptors and is unusual in being shared by two distinct polypeptide ligands: parathyroid hormone itself, a classic endocrine regulator of blood calcium, and parathyroid hormone-related protein, a local factor with prominent roles in skeletal development. Through a compact but information-rich signaling system, PTH1R converts the binding of these ligands into changes in gene expression, ion transport, and cell behavior across bone, kidney, and other tissues. This article reviews the structure of the receptor, the two ligands it serves, the intracellular pathways it engages, the physiological work it performs, what happens when it is altered by mutation, and why it remains a focus for both basic research and medicine.
Like all G protein-coupled receptors, PTH1R weaves seven times across the cell membrane in a bundle of transmembrane helices, with an intracellular face that couples to signaling proteins and an extracellular face that meets the ligand. What distinguishes the class B subfamily, to which PTH1R belongs, is a large amino-terminal extracellular domain that precedes the transmembrane bundle. This domain contributes to ligand capture, while the peptide portion of the ligand reaches deep into a pocket formed by the transmembrane helices to trigger activation. Structural studies using high-resolution cryo-electron microscopy have shown that, when bound to an activating peptide, the receptor adopts a conformation in which the transmembrane helices rearrange — most notably a pronounced kink in one helix — to create a surface that engages the stimulatory G protein. The extracellular domain is comparatively mobile, able to sample several orientations, which helps explain how a single receptor can accommodate related but distinct ligands. The architecture therefore couples a stable helical scaffold to a flexible capture domain, a design that underlies both specificity and adaptability.
Figure 1. Overall structures of PTH–PTH1R–Gq complexes. (Source: Sano FK, et al. 2025)
PTH1R is served by two endogenous ligands that share enough similarity in their amino-terminal regions to activate the same receptor but differ sharply in where and how they act. Parathyroid hormone is produced by the parathyroid glands and released into the circulation as a hormone whose primary job is to defend blood calcium: when calcium falls, more hormone is secreted, and the receptor-mediated responses raise it back toward normal. Parathyroid hormone-related protein, by contrast, is made by many tissues and acts mainly in a local, paracrine or autocrine manner; its best-characterized role is in the developing skeleton, where it guides the maturation of cartilage into bone. The receptor thus operates in two modes — as a systemic calcium sensor in the adult and as a local developmental cue during growth — and the same intracellular machinery is recruited for both. Research has shown that the two ligands can differ in how long they hold the receptor active, a property that turns out to be central to their distinct biological effects.
Binding of ligand sets off a branched intracellular response rather than a single linear cascade. The best-established route runs through the stimulatory G protein and adenylyl cyclase to raise cyclic AMP, which in turn activates protein kinase A and a set of downstream transcription factors that reshape cell behavior over hours. A second branch engages a different G protein that activates phospholipase C, generating inositol trisphosphate and intracellular calcium. A third limb recruits β-arrestin proteins, which classically promote receptor internalization and desensitization but also scaffold separate signaling modules. The existence of these parallel arms gives rise to the concept of biased agonism: different ligands, or the same ligand acting for different durations, can preferentially engage one arm over another. Research has established that the timing of receptor occupancy matters as much as the fact of occupancy — a brief, intermittent stimulus and a sustained, continuous one can produce opposite outcomes in the same tissue. This kinetic dimension is why the receptor is described less as an on-off switch and more as a tunable dial.
Figure 2. Diagram of ligand binding with PTH1R and the downstream signaling pathway. (Source: Zhao Y, et al. 2023)
In cartilage and bone, PTH1R is indispensable. During fetal and childhood growth, parathyroid hormone-related protein acting through the receptor keeps chondrocytes in the growth plate proliferating and properly timed in their maturation, so that long bones lengthen correctly; when this signal is absent, growth-plate development goes awry. After growth, parathyroid hormone itself acts on bone-forming cells and on the cells that resorb bone, and the net effect depends strongly on exposure pattern. Intermittent engagement of the receptor favors new bone formation, whereas prolonged engagement shifts the balance toward bone breakdown. This duality is the basis for how amino-terminal peptide analogs of the ligand are used to build bone in metabolic bone disease, and it illustrates a broader principle: the receptor's output is shaped by rhythm as much as by chemistry. The receptor therefore links a systemic calcium hormone to the continuous renewal of the skeleton.
The kidney is the other major site where PTH1R works to protect blood calcium. When the hormone engages the receptor in renal tubules, it promotes the reabsorption of calcium from the filtered urine back into the blood and reduces the loss of calcium in urine, while simultaneously encouraging phosphate excretion. It also stimulates the enzyme that converts vitamin D into its active hormonal form, which in turn increases intestinal calcium absorption. Together these actions restore calcium to its set point while adjusting phosphate in the opposite direction. Research has shown that the kidney and bone responses are coordinated through the same receptor, so that a change in ligand level is translated simultaneously into bone remodeling and renal handling of minerals. Disruption of receptor function in the kidney therefore disturbs not only calcium but the entire mineral-balance network that depends on active vitamin D.
The receptor's central role in bone and mineral metabolism makes it a long-standing target for peptide medicines. Amino-terminal fragments of parathyroid hormone and peptide analogs derived from parathyroid hormone-related protein are used clinically to stimulate bone formation in osteoporosis, where an intermittent regimen exploits the anabolic bias described above. Research continues into ligands that preferentially engage one signaling arm — for example favoring the β-arrestin pathway to promote bone formation while limiting calcium-mobilizing effects — a strategy made possible by the biased-agonism framework. The key point for the research and clinical communities is that the receptor's output can be steered by the shape and kinetics of the ligand, not only by its presence. This has sustained decades of interest in engineering peptides and small molecules that tune the receptor toward a desired response.
Studying PTH1R and its ligands depends on reagents that can detect the receptor and measure its activation. Defined-specificity antibodies are used to localize the receptor in tissues and to quantify it in lysates, while recombinant forms of the extracellular domain and of the full receptor support structural and binding studies. Assays that report cyclic AMP or receptor internalization provide functional readouts of activation, and immunoassays for the ligands themselves are the mainstay of endocrine measurement. As with other targets, the value of these tools tracks with their validation: an antibody that cleanly distinguishes PTH1R from related receptors, or a standard that calibrates an activation assay, is what allows a result to be compared across studies. For investigators working on calcium homeostasis, skeletal biology, or receptor pharmacology, well-characterized research-grade reagents for PTH1R remain essential infrastructure.
References
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| PTH1R | DAG-WT1693 | Recombinant Human PTH1R VLP | HEK293 cells | N/A | N/A | Inquiry |
Loading ......
